Walter J. Curran, Jr, MD, FACR, FASCO, executive director of Winship Cancer Institute of Emory University, associate vice president of Cancer at Woodruff Health Sciences Center, and Lawrence W. Davis Chair of Radiation Oncology at Emory University School of Medicine, explains the eligibility criteria for immunotherapy and radiation in patients with lung cancer.

Any fit patient with stage III lung cancer who comes out of chemoradiation in good condition without evidence of disease progression should be considered for adjuvant durvalumab (Imfinzi), irrespective of PD-L1 status, explains Curran.

In the metastatic setting, although no standard of care exists, ongoing clinical trials are examining the integration of high-dose radiation with immunotherapy, says Curran. Furthermore, the opportunity for stereotactic body radiation therapy is in the clinical trial setting, concludes Curran.

Videos

Walter J. Curran, Jr, MD, FACR, FASCO, explains the eligibility criteria for immunotherapy and radiation in patients with lung cancer.

Walter J. Curran, Jr, MD, FACR, FASCO

Articles

Dr. Curran on the Integration of Immunotherapy With Radiation Therapy in Lung Cancer